| SC 13D/A | 2020-04-06 | NEW ENTERPRISE ASSOCIATES 13 LP | Ra Pharmaceuticals, Inc. | - | - | EDGAR |
| SC 13G/A | 2020-02-10 | BlackRock Inc. | Ra Pharmaceuticals, Inc. | 4,488,324 | 9.5% | EDGAR |
| SC 13G/A | 2019-11-08 | WELLINGTON MANAGEMENT GROUP LLP | Ra Pharmaceuticals, Inc. | 179,804 | 0.4% | EDGAR |
| SC 13D/A | 2019-10-17 | NEW ENTERPRISE ASSOCIATES 13 LP | Ra Pharmaceuticals, Inc. | 6,135,234 | 13.0% | EDGAR |
| SC 13D/A | 2019-10-11 | RA CAPITAL MANAGEMENT, LLC | Ra Pharmaceuticals, Inc. | 3,971,750 | 8.4% | EDGAR |
| SC 13D/A | 2019-03-08 | MORGENTHALER VENTURE PARTNERS IX LP | Ra Pharmaceuticals, Inc. | 1,982,777 | 4.7% | EDGAR |
| SC 13G/A | 2019-02-12 | WELLINGTON MANAGEMENT GROUP LLP | Ra Pharmaceuticals, Inc. | 5,257,952 | 12.9% | EDGAR |
| SC 13G | 2019-02-08 | BlackRock Inc. | Ra Pharmaceuticals, Inc. | 2,645,261 | 6.5% | EDGAR |
| SC 13G/A | 2019-02-05 | Novartis Bioventures Ltd | Ra Pharmaceuticals, Inc. | 1,191,996 | 2.8% | EDGAR |
| SC 13D/A | 2019-01-22 | MORGENTHALER VENTURE PARTNERS IX LP | Ra Pharmaceuticals, Inc. | 2,119,525 | 5.0% | EDGAR |
| SC 13D/A | 2019-01-07 | MORGENTHALER VENTURE PARTNERS IX LP | Ra Pharmaceuticals, Inc. | 2,261,533 | 5.4% | EDGAR |
| SC 13D/A | 2018-12-31 | MORGENTHALER VENTURE PARTNERS IX LP | Ra Pharmaceuticals, Inc. | 2,584,477 | 6.1% | EDGAR |
| SC 13D/A | 2018-12-20 | NEW ENTERPRISE ASSOCIATES 13 LP | Ra Pharmaceuticals, Inc. | 6,135,234 | 15.0% | EDGAR |
| SC 13D/A | 2018-12-17 | RA Capital Healthcare Fund LP | Ra Pharmaceuticals, Inc. | 3,971,750 | 9.7% | EDGAR |
| SC 13D/A | 2018-12-12 | MORGENTHALER VENTURE PARTNERS IX LP | Ra Pharmaceuticals, Inc. | 2,659,128 | 8.2% | EDGAR |
| SC 13D/A | 2018-03-02 | Novo Holdings A/S | Ra Pharmaceuticals, Inc. | 1,531,562 | 4.9% | EDGAR |
| SC 13D/A | 2018-02-27 | NEW ENTERPRISE ASSOCIATES 13 LP | Ra Pharmaceuticals, Inc. | 5,490,073 | 17.7% | EDGAR |
| SC 13D/A | 2018-02-26 | Novo Holdings A/S | Ra Pharmaceuticals, Inc. | 2,031,562 | 6.5% | EDGAR |
| SC 13D/A | 2018-02-16 | RA CAPITAL MANAGEMENT, LLC | Ra Pharmaceuticals, Inc. | 3,135,084 | 10.3% | EDGAR |
| SC 13G/A | 2018-02-08 | WELLINGTON MANAGEMENT GROUP LLP | Ra Pharmaceuticals, Inc. | 2,767,243 | 12.2% | EDGAR |